A revolutionary weight loss pill changes the fight against obesity. Patients lose up to 12 pounds in a few weeks
A new drug developed by the Eli Lilly Pharmaceutical Company promises to revolutionize the treatment of obesity. The pill provides patients with an alternative to weight loss injections. Clinical studies have shown that Orphorglipron, administered daily, can cause a medium weight loss of 12 kg.
The pill will help to get rid of injections those who suffer from obesity / photo source: Pharmamanage
A study in which a new weight loss pill was evaluated with daily administration found that people who take this medicine can lose from kilograms in a few weeks, treatment offering obese people “convenient” to injections, DPA/PA Media, quoted by Agerpres, reports on Friday.
American pharmaceutical company Eli Lilly said he is expecting a substantial demand after the new pill is launched on the market.
Eli Lilly indicated that he will request the approval of the international regulatory authorities, with the publication of the results of a large study on Orphlipron.
Pill helps patients lose weight in a very short time
The new pill is an agonist of the GLP-1, a type of drug that contributes to lowering the blood sugar level, slows digestion and can reduce appetite.
According to the new data of the study on orphorglipron, People who took this medicine lost, on average, 12.3 kilograms during the 72 weeks of treatment compared to those who did not take this pill.
Three out of five (60%) of people who have taken the maximum dose of Orphoripron lost at least 10% of body weight, while 40% lost at least 15% of weight, according to the study to be presented at the annual meeting of the European Association for Diabetes (EASD) study of 2025.
In addition to weight loss, the people who participated in the study and received this medicine presented other Health benefits, including improvements in cholesterol levels, blood pressure and risk of heart disease.
Experts have stressed that these tablets do not seem to provide the same benefits as some weight loss injections, but said they will be more “tolerable” for many patients.
Lilly said that the tablet safety profile is similar to that of other GLP-1 drugs, the most common side effect being gastrointestinal disorders.
tablet was evaluated in a study conducted on 3,127 obese or overweight adults, with medical problems associated with excessive weight and did not suffer from diabetes.
“With orphorglipron, we work to transform care in obesity by introducing a potential oral therapy with administration once a day, which could support early intervention and long -term management, while offering a convenient alternative to injectable treatments,” Kenneth Custer said on Thursday.
“With these positive data available, we intend to submit the orphypron of the assessment of the regulatory authorities by the end of the year and we are prepared for a global launch, to meet this urgent need for public health,” he said.
The news comes in the context in which a separate study has highlighted the potential additional benefits of GLP-1-agonists of glucagon-like Peptide-1. This compound has been initially developed as a treatment for people with type 2 diabetes and is currently widely used in the treatment of obesity and, in general, for weight loss.
What does studies look like on the administration of these drugs
A study published by McGill University and the Lady Davis Institute for medical research from Jewish General Hospital in Canada, examined the benefits of these drugs beyond weight loss, analyzing research that evaluated these drugs in other fields of medicine.
Experts have stated in the scientific journal Eclinicalmedicine that GLP-1 can also play an important role in improving liver disease, sleep apnea, knee arthritis, polycystic ovary syndrome, Parkinson's disease, Alzheimer's disease and substance abuse.
However, they also emphasized possible safety problems associated with these drugs, including in the pancreas and gallbladder.
“The therapeutic landscape for obesity and associated metabolic disorders has evolved substantially with the appearance of GLP-1 RA,” they wrote. “These agents now play a central role not only in weight management and diabetes care, but they are also investigated in an increasing number of conditions, including cardiovascular, renal, hepatic, neurological and substance consumption. As their indications extend, it is necessary to extend to us, Patient -centered, “the specialists noted.
The manufacturer also manufactures Mounjaro, nicknamed “King Kong of weight loss injections.”
The occurrence of weight loss injections was greeted by health specialists. However, they involve additional effort for already overloaded medical services. Thus, medicines in the form of tablets, which are expected to be cheaper and easier to administer, can provide new hope for millions of people who want to lose weight.
